{"id":"NCT01919801","sponsor":"Shire","briefTitle":"Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema","officialTitle":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-02","primaryCompletion":"2015-08-22","completion":"2015-08-22","firstPosted":"2013-08-09","resultsPosted":"2016-10-10","lastUpdate":"2021-06-08"},"enrollment":118,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Angiotensin Converting Enzyme Inhibitor Induced Angioedema"],"interventions":[{"type":"DRUG","name":"Icatibant","otherNames":["Firazyr"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Icatibant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to compare the safety and efficacy of icatibant with placebo in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults.","primaryOutcome":{"measure":"Time to Meeting Discharge Criteria (TMDC)","timeFrame":"Day 0 up to Day 5","effectByArm":[{"arm":"Icatibant 30 mg","deltaMin":4.03,"sd":null},{"arm":"Placebo","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.633"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":55,"countries":["United States","Canada","Israel","United Kingdom"]},"refs":{"pmids":["28552382"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":60},"commonTop":["Headache","Angioedema","Dysphonia","Dyspnoea","Nausea"]}}